Investigational Drug Information for Tavilermide
✉ Email this page to a colleague
What is the development status for investigational drug Tavilermide?
Tavilermide is an investigational drug.
There have been 5 clinical trials for Tavilermide.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2015.
The most common disease conditions in clinical trials are Keratoconjunctivitis Sicca, Dry Eye Syndromes, and Keratoconjunctivitis. The leading clinical trial sponsors are Mimetogen Pharmaceuticals USA, Inc. and [disabled in preview].
There are six US patents protecting this investigational drug and sixty-four international patents.
Summary for Tavilermide
| US Patents | 6 |
| International Patents | 64 |
| US Patent Applications | 18 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 3 |
| Clinical Trial Progress | Phase 3 (2015-12-01) |
| Vendors | 25 |
Recent Clinical Trials for Tavilermide
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye | Mimetogen Pharmaceuticals USA, Inc. | Phase 3 |
| Tavilermide Ophthalmic Solution for the Treatment of Dry Eye | Mimetogen Pharmaceuticals USA, Inc. | Phase 3 |
| A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease | Mimetogen Pharmaceuticals USA, Inc. | Phase 3 |
Clinical Trial Summary for Tavilermide
Top disease conditions for Tavilermide
Top clinical trial sponsors for Tavilermide
US Patents for Tavilermide
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tavilermide | ⤷ Sign Up | Kinase inhibitors | Respivert Limited (High Wycombe, Buckinghamshire, GB) Topivert Pharma Limited (London, GB) | ⤷ Sign Up |
| Tavilermide | ⤷ Sign Up | Kinase inhibitors | Respivert Limited (N/A) Topivert Pharma Limited (London, GB) | ⤷ Sign Up |
| Tavilermide | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Tavilermide | ⤷ Sign Up | Kinase inhibitor | Respivert Limited (Buckinghamshire, GB) Topivert Pharma Limited (London, GB) | ⤷ Sign Up |
| Tavilermide | ⤷ Sign Up | Kinase inhibitors | RESPIVERT LIMITED (Buckinghamshire, GB) TOPIVERT PHARMA LIMITED (London, GB) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tavilermide
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tavilermide | Australia | AU2017245888 | 2036-04-06 | ⤷ Sign Up |
| Tavilermide | Brazil | BR112018067552 | 2036-04-06 | ⤷ Sign Up |
| Tavilermide | Canada | CA3015978 | 2036-04-06 | ⤷ Sign Up |
| Tavilermide | China | CN109071505 | 2036-04-06 | ⤷ Sign Up |
| Tavilermide | Eurasian Patent Organization | EA201892213 | 2036-04-06 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
